Balyasny Asset Management
ICPT

Balyasny Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Balyasny Asset Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-105,000
Closed -$12.5M – 1851
2018
Q3 		$12.5M Buy
105,000
+62,000
+144% +$6.56M 0.06% 416
2018
Q2 		$3.61M Buy
+43,000
New +$3.15M 0.02% 754

Balyasny Asset Management's ICPT Position: Q1 2023 in Review

Balyasny Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2023, closing a stake of 364,068 shares — an estimated $4.5M sold.

Balyasny Asset Management first reported a position in ICPT in Q3 2016 and held it in 14 quarters. The position peaked at $13.8M in Q2 2017. 144 funds tracked by Wall St. Rank hold ICPT as of Q1 2023.

  • Balyasny Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 364,068 Intercept Pharmaceuticals, Inc. shares in Q1 2023, an estimated $4.5M.
  • Balyasny Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2016 and held it in 14 quarters.
  • Balyasny Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $13.8M in Q2 2017.
  • 144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2023.

Based on Balyasny Asset Management's 13F filing for Q1 2023, filed 15 May 2023.